No price history available.
Key financial summary
Financials in THB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | THBm | 12,589 | 14,136 | 15,686 | 15,681 | 15,344 | 14,147 | N/A | N/A |
| Operating profit | THBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | THBm | 1,393 | 1,947 | 2,242 | 1,993 | 2,012 | 1,912 | N/A | N/A |
| EPS reported | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | THBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | THBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | THBm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | THB | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in THB| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Established in Bangkok, Thailand, in 1982, Mega Lifesciences Public Company Limited, a subsidiary of Unistretch Limited, operates as a comprehensive pharmaceutical and wellness enterprise. Its primary activities encompass the development, promotion, and distribution of a broad spectrum of health-related products, including nutritional supplements, prescription medicines, over-the-counter (OTC) remedies, botanical solutions, vitamins, and everyday consumer goods. The company structures its operations across three main divisions: Brands, Distribution, and Original Equipment Manufacture. Mega Lifesciences offers an extensive array of complementary medicines targeting various health concerns such as bone and joint health, pediatric care, diabetes management, cardiovascular support, digestive and liver wellness, skin health, weight management, overall well-being, men's and women's specific needs, and sports nutrition. Its OTC portfolio addresses common issues like gastrointestinal discomfort and pain. Furthermore, the prescription drug division covers crucial therapeutic areas including iron deficiency, anticoagulation, diabetology, cardiology, dermatology, gastroenterology, neurology, pain relief, osteoporosis, respiratory conditions, urology, oncology, and nephrology. Beyond its proprietary product lines, the company also provides third-party logistical and marketing services. Additionally, Mega Lifesciences is involved in managing wellness centers and offers specialized services in software design, development, and related technological solutions. The company maintains a significant global footprint, with operations spanning the Asia Pacific region, the Middle East, Africa, and the Commonwealth of Independent States.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Mega Lifesciences Public Company Limited (MEGA.BK)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Established in Bangkok, Thailand, in 1982, Mega Lifesciences Public Company Limited, a subsidiary of Unistretch Limited, operates as a comprehensive pharmaceutical and wellness enterprise. Its primary activities encompass the development, promotion, and distribution of a broad spectrum of health-related products, including nutritional supplements, prescription medicines, over-the-counter (OTC) remedies, botanical solutions, vitamins, and everyday consumer goods. The company structures its operations across three main divisions: Brands, Distribution, and Original Equipment Manufacture. Mega Lifesciences offers an extensive array of complementary medicines targeting various health concerns such as bone and joint health, pediatric care, diabetes management, cardiovascular support, digestive and liver wellness, skin health, weight management, overall well-being, men's and women's specific needs, and sports nutrition. Its OTC portfolio addresses common issues like gastrointestinal discomfort and pain. Furthermore, the prescription drug division covers crucial therapeutic areas including iron deficiency, anticoagulation, diabetology, cardiology, dermatology, gastroenterology, neurology, pain relief, osteoporosis, respiratory conditions, urology, oncology, and nephrology. Beyond its proprietary product lines, the company also provides third-party logistical and marketing services. Additionally, Mega Lifesciences is involved in managing wellness centers and offers specialized services in software design, development, and related technological solutions. The company maintains a significant global footprint, with operations spanning the Asia Pacific region, the Middle East, Africa, and the Commonwealth of Independent States.